Results, Benefit Assessment, Price, negotiation, Pharma Pricing

Latest results of early benefit assessments and price negotiations

At Pharma Pricing 2014, Meriem Bouslouk PhD, Pharmaceuticals Department, Federal Joint Committee Germany gave a presentation “Latest results of early benefit assessments and price negotiations” Download and learn: Assessment principles- Key points Consultations with the G-BA Orphan Drugs Price negotiations / Arbitration Decisions / OPT-OUTS G-BA vision at European level Licensing and reimbursing: harmonization? Download presentation Found this interesting? You might …

value, assessment

Value based assessment: NICE’s role

At Pharma Pricing & Market Access Europe 2014, David Haslam, Chairman, NICE, gave a presentation on “Value based assessment: NICE’s role” Haslam’s presentation discussed  incorporating burden of illness and wider societal impact into NICE’s technology assessment methods. Download and learn: Value Based Assessment NICE’s current approach Costs and benefits New DH terms of reference Approaches to appraising the impact of technologies …

Download: Top challenges in assessing the safety for a new compound

At Exploratory Clinical Development World Europe 2013, we gathered several high level attendees and produced video interviews discussing the topic: “What are the challenges in assessing the safety for a new compound?” These video interviews have been gathered and presented in the following ebook and contain feedback from: Maria Hernandez Fuentes, Kings College London Fred Pritchard, Celerion James Dow, Daiichi …

Guest Post: Rapid Effectiveness Assessment Process Could Shape HTA in Eastern Europe

This article was provided by Richard Staines of APM Health Europe from its coverage of the recent Health Technology Assessment World conference in London. A rapid European effectiveness assessment process comparing new drugs to standard of care could provide key data for local health technology assessment (HTA) in smaller European countries, experts have been told. However, Wim Goettsch, project leader …

Download ebook: Top challenges in HTA

    In today's austere times, payers are continuing to control escalating healthcare costs, relying on health technology assessment agencies in order to make purchasing decisions and effective use of funds.  HTA is an important part of evidence-based health decision-making in most EU countries with ever increasing demands for value demonstration proving your drugs are most beneficial to patients. This …

Download: What happens after the benefit assessment?

Prof. Dr. Frank–Ulrich Fricke, Technische Hochschule Nürnberg Georg Simon Ohm gave a presentation at Health Technology Assessment World last December on "What happens after the benefit assessment." Download his presentation and learn: What happens after the benefit assessment Implications of the G-BA resolution The negotiation process Price negotations in a nutshell Objectives of the Arbitration Process Download the presentation This …

Robin Geller, Baxter Healthcare Corporation, on the #Pharmacovigilance industry

Continuing with our series on the current pharmacovigilance industry we spoke with Robin Geller, Director of Risk Management and Safety Writing Global Pharmacovigilance, at Baxter Healthcare Corporation What is the biggest change that you are seeing in pharma's drug safety strategies at the moment? The continuing shift from submission of individual case reports to aggregate analysis, signal detection and risk …

Topics to be covered at #DrugSafety Europe

If you can't make our Drug Safety USA event taking place next week, why not check out our European event coming up in September? The brochure is due out in a few weeks but see below for a sneak preview of some of the presentations due to take place: In depth review of the new European pharmacovigilance legislation Operational implications …

Who has previously attended Drug Safety World?

  The World Drug Safety Congress Americas will provide you with the opportunity to meet and network with the big names in the industry. If you are thinking of attending but aren't sure who will be there, check out the list below of previous companies who have come to the event in the past.   If you are interested in …